NasdaqGS:PGNYHealthcare
Progyny (PGNY) Drew Fresh Attention After Its Outlook, Is It 25% Below Fair Value?
Progyny (PGNY) has come into focus after recent coverage highlighted its liquidity, operational efficiency and growth profile, following Q2 2026 revenue growth of 5.3% and full year revenue expectations of US$1.36b to US$1.385b.
See our latest analysis for Progyny.
Progyny’s recent Q2 update and revenue outlook appear to have drawn fresh attention, even as the 30 day share price return is down 18.46% and the year to date share price return is down 1.19%, while the 1 year total shareholder...